Nanobiotix to participate in H.C. Wainwright global investment conference

0 min read | Published on 10 Sept 2026, 03:57 AM |Updated on 10 Sept 2026, 03:57 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Nanobiotix plans to participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026
The event is scheduled for 12:00 pm EDT / 6:00 pm CEST in New York, NY
Presenters include Laurent Lévy, Chief Executive Officer, and Bart Van Rhijn, Chief Financial and Business Officer
Nanobiotix holds more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability, and central nervous system disorders
The company is listed on Euronext Paris since 2012 and on Nasdaq since December 2020

*this image is generated using AI for illustrative purposes only.

Nanobiotix will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York.

Conference participation details

Company management will represent Nanobiotix at the event. The following table summarises the key details of the appearance:

Parameter	Details
Conference	H.C. Wainwright 28th Annual Global Investment Conference
Date	September 15, 2026
Time	12:00 pm EDT / 6:00 pm CEST
Location	New York, NY
Presenters	Laurent Lévy, Chief Executive Officer; Bart Van Rhijn, Chief Financial and Business Officer

About Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches with applications in oncology and other major diseases. Incorporated in 2003 and headquartered in Paris, France, the company has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. It also maintains subsidiaries in Cambridge, Massachusetts, among other locations.

The company holds more than 30 umbrella patents associated with three nanotechnology platforms covering:

Oncology
Bioavailability and biodistribution
Disorders of the central nervous system

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific clinical trial milestones or regulatory updates for Nanobiotix's oncology pipeline are investors likely to anticipate from the CEO's remarks?

How might the company's recent financial performance or burn rate influence the strategic priorities discussed by the CFO during the fireside chat?

Are there indications that Nanobiotix is exploring new partnership opportunities or licensing deals for its central nervous system platform in the near future?

Nanobiotix reports 50.8 million shares outstanding as of July 31, 2026

0 min read | Published on 26 Aug 2026, 01:52 AM |Updated on 26 Aug 2026, 01:52 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Nanobiotix reported 50,833,462 shares outstanding as of July 31, 2026
Total theoretical voting rights stood at 54,534,179
Exercisable voting rights were recorded at 54,512,061
Disclosure complies with French Commercial Code and AMF regulations

*this image is generated using AI for illustrative purposes only.

Nanobiotix disclosed its share capital and voting rights structure as of July 31, 2026, reporting 50,833,462 shares outstanding.

The late-stage clinical biotechnology company filed the disclosure in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers).

Share Capital and Voting Rights

The filing details the breakdown between theoretical and exercisable voting rights for shareholders.

Metric	Count
Shares Outstanding	50,833,462
Theoretical Voting Rights	54,534,179
Exercisable Voting Rights	54,512,061

Theoretical voting rights serve as the basis for calculating threshold crossings under Article 223-11 of the AMF General Regulations. This figure includes all shares with attached voting rights, even those with suspended rights.

Exercisable voting rights represent the net count available at shareholders’ meetings. This calculation excludes shares held in treasury by the company where voting rights are suspended.

About Nanobiotix

Nanobiotix is headquartered in Paris and listed on Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches across oncology, bioavailability, and central nervous system disorders.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the discrepancy between theoretical and exercisable voting rights influence potential takeover defenses or shareholder activism at Nanobiotix?

What impact could the current share capital structure have on upcoming dilution risks associated with late-stage clinical trial funding requirements?

Are there any pending regulatory filings or corporate actions that might explain the specific composition of treasury shares affecting exercisable voting rights?